Immunotherapy after chemoradiation for high-risk head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of head and neck squamous cell cancer (like in the mouth, throat, voice box, or neck area).
- Your cancer must have at least one high-risk feature, such as a large tumor, spread to many neck lymph nodes, or cancer cells found around nerves or blood vessels.
- You must be able to get around and take care of yourself (ECOG score 0 or 1).
- Your tumor must have a certain level of a protein called PD-L1 (CPS > 1).
- You cannot have a history of autoimmune disease (except cured childhood asthma or vitiligo) or active infections like HIV or hepatitis.
- You must not have had treatment with a PD-1 or PD-L1 drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This trial compares two different treatments for people who have already had surgery for advanced head and neck cancer and responded very well to chemotherapy plus immunotherapy before surgery. It tests whether continuing with immunotherapy or receiving radiation therapy is better at preventing the cancer from coming back.
This Phase 2 study looks at what treatment is best after you first receive chemotherapy plus immunotherapy, then have surgery for head and neck squamous cell cancer. It tries to use how your tumor responds (shown in lab tissue after treatment) to guide the next steps, which may improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.